A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma

LESSONS LEARNED. Pazopanib shows a modest efficacy in metastatic alveolar soft part sarcoma. Clinical outcomes were comparable to those in previous studies using antiangiogenic drugs. Further prospective studies evaluating the benefit of pazopanib in alveolar soft part sarcoma with a larger sample a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Miso, Kim, Tae Min, Keam, Bhumsuk, Kim, Yu Jung, Paeng, Jin Chul, Moon, Kyung Chul, Kim, Dong‐Wan, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324645/
https://www.ncbi.nlm.nih.gov/pubmed/30254189
http://dx.doi.org/10.1634/theoncologist.2018-0464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324645/
https://www.ncbi.nlm.nih.gov/pubmed/30254189
http://dx.doi.org/10.1634/theoncologist.2018-0464

Ejemplares similares